<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4793">
  <stage>Registered</stage>
  <submitdate>22/07/2014</submitdate>
  <approvaldate>22/07/2014</approvaldate>
  <nctid>NCT02198651</nctid>
  <trial_identification>
    <studytitle>A Phase 4 Trial Assessing the ImPact of Residual Inflammation Detected Via Imaging TEchniques, Drug Levels and Patient Characteristics on the Outcome of Dose TaperIng of Adalimumab in Clinical Remission Rheumatoid ArThritis (RA) Subjects (PREDICTRA)</studytitle>
    <scientifictitle>A Phase 4 Trial Assessing the ImPact of Residual Inflammation Detected Via Imaging TEchniques, Drug Levels and Patient Characteristics on the Outcome of Dose TaperIng of Adalimumab in Clinical Remission Rheumatoid ArThritis (RA) Subjects (PREDICTRA)</scientifictitle>
    <utrn />
    <trialacronym>PREDICTRA</trialacronym>
    <secondaryid>2014-001114-26</secondaryid>
    <secondaryid>M14-500</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Rheumatoid Arthritis</healthcondition>
    <healthcondition>Musculoskeletal and Connective Tissue Diseases</healthcondition>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Osteoarthritis</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Rheumatoid arthritis</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Skin</conditioncode1>
      <conditioncode2>Other skin conditions</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Adalimumab
Other interventions - Placebo

Active Comparator: Adalimumab - Subcutaneous (SC) every three weeks in the Double-Blind period from Week 4 to Week 40

Placebo Comparator: Placebo - SC every 3 weeks from Week 4 to Week 40

Experimental: Open Label Adalimumab - Adalimumab sc every other week from Week 0 to Week 4

Experimental: Open-Label Rescue Arm - Adalimumab sc every other week from Flare Week 0 to Flare Week 16


Treatment: drugs: Adalimumab
Subcutaneously

Other interventions: Placebo
Subcutaneously in the double blind period

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Hand and wrist synovitis rheumatoid arthritis magnetic resonance imaging (MRI) scoring system (RAMRIS) score - Synovitis is assessed in three wrist regions (the distal radioulnar joint; the radiocarpal joint; the intercarpal and carpometacarpal joints) and in each Metacarpophalangeal joint (MCP) joint. The first carpometacarpal joint and the first MCP joint are not scored. The scale is 0-3. Score 0 is normal, and 1-3 (mild, moderate, severe) are by thirds of the presumed maximum volume of enhancing tissue in the synovial compartment.</outcome>
      <timepoint>At Week 4</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Bone Marrow Edema (BME) RAMRIS score - Bone edema in each bone is scored separately. The scale is 0-3 based on the proportion of bone with edema, as follows0: no edema; 1: 1-33% of bone edematous; 2: 34-66% of bone edematous; 3: 67-100%</outcome>
      <timepoint>At Week 4</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Composite of Hand, Wrist and BME RAMRIS scores - The composite score is the sum of synovitis and bone edema scores.</outcome>
      <timepoint>At Week 4</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Flare occurrence - Flare is defined as an increase from double blind (db) Baseline in DAS (Disease Activity Score) 28 Erythrocyte sedimentation rate (ESR) of &gt; 0.6 AND DAS28 [ESR] &gt; 2.6, OR an increase in DAS28 (ESR) of = 1.2 irrespective of the resulting DAS28 [ESR].</outcome>
      <timepoint>From Week 4 to Week 40</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Time to flare - Flare is defined as an increase from db Baseline in DAS28 [ESR] of &gt; 0.6 AND DAS28 [ESR] &gt; 2.6, OR an increase in DAS28 (ESR) of = 1.2 irrespective of the resulting DAS28 [ESR].</outcome>
      <timepoint>From Week 4 to Week 40</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Flare severity - It is assessed using Likert scale 0-10.</outcome>
      <timepoint>From Week 4 to Week 40</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of subjects who regain clinical remission in the Open-Label Rescue Arm over time - Remission defined as DAS28 (ESR) &lt; 2.6 and defined as DAS28 (ESR) decrease &gt;1.2 if DAS28 (ESR) was less than 2.6 at flare</outcome>
      <timepoint>From Flare Week 0 to Flare Week 16</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to regain clinical remission in the Open-Label Rescue Arm - Clinical remission is defined as DAS28 [ESR] &lt; 2.6 and defined as DAS28 (ESR) decrease &gt; 1.2 if DAS28 [ESR] was less than 2.6 at flare.</outcome>
      <timepoint>From Flare Week 0 to Flare Week 16</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of subjects who achieve low disease activity in the Open-Label Rescue Arm over time - Low disease activity defined as DAS28 (ESR) &lt; 3.2</outcome>
      <timepoint>From Flare Week 0 to Flare Week 16</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in DAS28 (ESR) - Assessed by the change in DAS28 (ESR) from Week 4 to Week 40 and Flare Week 0 to Flare Week 16 in the Open-Label Rescue Arm.</outcome>
      <timepoint>From Week 4 to Week 40 and from Flare Week 0 to Flare Week 16</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of subjects maintaining clinical remission throughout the study - Clinical remission defined by DAS, SDAI and CDAI: DAS28 Erythrocyte sedimentation rate (ESR) &lt; 2.6; SDAI = 3.3; CDAI = 2.8)]</outcome>
      <timepoint>From Week 4 to Week 40</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in MRI synovitis - Synovitis is assessed in three wrist regions (the distal radioulnar joint; the radiocarpal joint; the intercarpal and carpometacarpal joints) and in each Metacarpophalangeal joint (MCP) joint. The first carpometacarpal joint and the first MCP joint are not scored. The scale is 0-3. Score 0 is normal, and 1-3 (mild, moderate, severe) are by thirds of the presumed maximum volume of enhancing tissue in the synovial compartment.</outcome>
      <timepoint>From Week 4 to Week 40 or Final visit</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in Health Assessment Questionnaire - Disability Index (HAQ-DI) over time in the open-label rescue arm - Assessed by the HAQ-DI which has 8 sections and 2-3 questions per section. Scoring within each section is from 0 (without any difficulty) to 3 (unable to do). The scores are summed and divided by 8.</outcome>
      <timepoint>From Flare Week 0 to Flare Week 16</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of subjects with HAQ-DI normal - HAQ-DI = 0.5 is considered to be normal.</outcome>
      <timepoint>From Week 4 to Week 40</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in RAPID 3 scores assessed during in-office visits - Assessed by RAPID-3 questionnaire which includes a subset of core variables found in the multi-dimensional HAQ, a patient global assessment for pain and a patient global assessment for health.</outcome>
      <timepoint>From Week 4 to Week 40 and from Flare Week 0 to Flare Week 16</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in RAPID 3 at home assessments - Assessed weekly by RAPID-3 questionnaire which includes a subset of core variables found in the multi-dimensional HAQ, a patient global assessment for pain and a patient global assessment for health.</outcome>
      <timepoint>From Flare Week 0 to Flare Week 16</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in Treatment Satisfaction Questionnaire for Medication (TSQM) in the open-label rescue arm - Assessed by the TSQM questionnaire for medication which gathers patient evaluation of the effectiveness, side effects and convenience of the medication through 14 questions.</outcome>
      <timepoint>From Week 4 to Week 40 and Flare Week 0 to Flare Week 16</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in Work Productivity and Activity Impairment (WPAI) - Assessed by the WPAI containing questions related with employment status, the number of missed work hours, the number of working hours and productivity related questions.</outcome>
      <timepoint>From Week 4 to Week 40 and from Flare Week 0 to Flare Week 16</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in Short Form-36 (SF-36) - Assessed by SF-36 survey questionnaire containing 11 questions directed to patients related to their health and well being.</outcome>
      <timepoint>From Week 4 to Week 40 and from Flare Week 0 to Flare Week 16</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in Functional Assessment of Chronic Illness Therapy - fatigue (FACIT-fatigue) - Assessed by the FACIT-fatigue questionnaire evaluating standardized statements related with fatigue in rated in a scale from 0-4.</outcome>
      <timepoint>From Week 4 to Week 40 and from Flare Week 0 to Flare Week 16</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Clinical Disease Activity Index (CDAI) - CDAI is evaluated by the sum of 28 tender joint count, 28 swollen joint count, physician global assessment and patient global assessment.</outcome>
      <timepoint>From Week 4 to Week 40 and from Flare Week 0 to Flare Week 16</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in Simplified Disease Activity Index (SDAI) - SDAI is evaluated by the sum of 28 tender joint count, 28 swollen joint count, physician global assessment, patient global assessment and c-reactive protein.</outcome>
      <timepoint>From Week 4 to Week 40 and from Flare Week 0 to Flare Week 16</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in BME - Bone edema in each bone is scored separately. The scale is 0-3 based on the proportion of bone with edema, as follows0: no edema; 1: 1-33% of bone edematous; 2: 34-66% of bone edematous; 3: 67-100%</outcome>
      <timepoint>From Week 4 to Week 40 or Final visit</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in erosions RAMRIS scores - Bone erosions in each bone (wrists: carpal bones, distal radius, distal ulna, metacarpal bases; MCP joints: metacarpal heads, phalangeal bases) is scored separately. The scale is 0-10, based on the proportion of eroded bone compared to the ''assessed bone volume'', judged on all available images0: no erosion; 1: 1-10% of bone eroded; 2; 11-20%, etc.</outcome>
      <timepoint>From Week 4 to Week 40</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Subject has a diagnosis of rheumatoid arthritis (RA) as defined by the 1987 revised
             American College of Rheumatology (ACR) classification criteria and/or the ACR
             /European League Against Rheumatism (EULAR) 2010 classification criteria (any duration
             since diagnosis).

          2. Subject must meet the following criteria:

               -  Must be treated with adalimumab 40 mg sc eow for at least 12 months prior to Week
                  0 Visit

               -  Must be treated with concomitant MTX at a stable dose (oral, sc or im at any
                  dose) for at least 12 weeks prior to Week 0 Visit or if not on MTX, must be
                  treated with other allowed csDMARDs at stable dose for at least 12 weeks prior to
                  Week 0 Visit or if not treated with csDMARDs must maintain this regimen for at
                  least 12 weeks prior to Week 0 Visit.

          3. Subject must be in sustained clinical remission based on the following:

               -  At least one documented 4 or 3 (if PGA is not available) variables DAS28 (ESR) or
                  DAS28 (CRP) &lt; 2.6 (or calculated based on documented components of the DAS28) in
                  the patient chart 6 months or longer prior to the Screening Visit;

               -  4 variables DAS28 (ESR) assessed at Screening &lt; 2.6, with all components
                  including ESR assessed at Screening.

          4. If subjects are receiving concomitant allowed csDMARDs (in addition or not to MTX) the
             dose must be stable for at least 12 weeks prior to the Week 0 Visit (e.g.,
             chloroquine, hydroxychloroquine, sulfasalazine, gold formulations [including
             auranofin, gold sodium thiomalate, and aurothioglucose] and/or leflunomide).

          5. If subjects are receiving concomitant oral corticosteroids, prednisone or equivalent
             must be &lt; 10 mg/day and the dose must be stable for at least 4 weeks prior to the
             Screening Visit.

          6. If subjects are receiving concomitant non-steroidal anti-inflammatory drugs (NSAIDs),
             tramadol or other equivalent opioids and/or non-opioid analgesics, the dose and/or
             therapeutic scheme must be stable for at least 4 weeks prior to the Week 0 Visit.

          7. Subject must be able and willing to provide written informed consent and comply with
             the requirements of this study protocol.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>99</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Any 4 or 3 (if PGA is not available) variables DAS28 (ESR) or DAS28 (CRP) (or
             calculated based on documented components of the DAS28) assessed within 6 months prior
             to the Screening Visit = 2.6.

          2. Subject is on an additional concomitant biological disease-modifying anti-rheumatic
             drug (bDMARD) (including but not limited to abatacept, anakinra, certolizumab,
             etanercept, golimumab, infliximab, rituximab or tocilizumab).

          3. Subject has been treated with intra-articular or parenteral corticosteroids within the
             last four weeks before Screening.

          4. Subject has undergone joint surgery within 12 weeks of Screening (at joints to be
             assessed by magnetic resonance imaging (MRI) and/or ultrasound).

          5. Subject has a medical condition precluding an MRI (e.g. magnetic activated implanted
             devices - cardiac pace-maker, insulin pump, neuro stimulators, etc. and metallic
             devices or fragments or clips in the eye, brain or spinal canal and in the hand/wrist
             undergoing MRI)

          6. Subject has a medical condition precluding a contrast MRI with gadolinium [e.g.
             nephrogenic systemic fibrosis, previous anaphylactic/anaphylactoid reaction to
             gadolinium containing contrast agent, pregnancy or breast feeding, severe renal
             insufficiency with an estimated Glomerular Filtration Rate (eGFR) below 0
             mL/min/1.73m2 at Screening, hepato-renal syndrome, severe chronic liver function
             impairment]

          7. Subject has been treated with any investigational drug of chemical or biologic nature
             within a minimum of 30 days or five half-lives (whichever is longer) of the drug prior
             to the Screening Visit.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate />
    <actualstartdate>15/12/2014</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>200</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>2/01/2020</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Royal Prince Alfred Hospital /ID# 154649 - Camperdown</hospital>
    <hospital>Optimus Clinical Research Pty. Ltd. /ID# 133881 - Kogarah</hospital>
    <hospital>Coast Joint Care /ID# 133883 - Maroochydore</hospital>
    <hospital>John Hunter Hospital /ID# 133884 - New Lambton Heights</hospital>
    <postcode>2050 - Camperdown</postcode>
    <postcode>2217 - Kogarah</postcode>
    <postcode>4558 - Maroochydore</postcode>
    <postcode>2305 - New Lambton Heights</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Alabama</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Louisiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Mississippi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>South Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Vienna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Hamilton</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Montreal</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Newmarket</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Sherbrooke</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Amiens</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Echirolles</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Le Coudray</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Poitiers</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Bad Abbach</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin-Buch</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Cologne Porz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hamburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Munich</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Ratingen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Rendsburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Greece</country>
      <state>Athens</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Greece</country>
      <state>Chaidari</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Greece</country>
      <state>Heraklion crete</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Budapest</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Debrecen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ireland</country>
      <state>Dublin 4</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Bari</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Milan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Pavia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Rome</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Verona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Amsterdam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Arnhem</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Leeuwarden</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Utrecht</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Bilbao</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>El Palmar, Murcia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Sant Joan Despi, Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Santiao de Compostela</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Valencia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Lund</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Uppsala</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Vasteras</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Chelmsford Essex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Cosham, Hants</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Edinburghy</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Leeds</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Liverpool</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Se1 9rt</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>AbbVie</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>A Phase 4 Trial Assessing the ImPact of Residual Inflammation Detected via Imaging
      TEchniques, Drug Levels and Patient Characteristics on the Outcome of Dose TaperIng of
      Adalimumab in Clinical Remission Rheumatoid ArThritis (RA) Subjects (PREDICTRA).</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02198651</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Maja Hojnik, MD</name>
      <address>AbbVie</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>